| Status | Awaiting development |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | The topic routing was discussed at the Topic Selection Oversight Panel (TSOP) in April 2023. The panel concluded that the topic was suitable for a Technology Appraisal. Please see project documents for further details |
| Process | STA Standard |
| ID number | 3959 |
Project Team
| Project lead | Michelle Adhemar |
Email enquiries
- If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 October 2023 | Following a routing challenge raised by the company, regarding the Topic Selection Oversight Panel (TSOP) decision to route Beremagene Geperpavec as a Technology Appraisal, the start of this evaluation is delayed. The timelines for the evaluation will be confirmed once TSOP have reviewed the challenge. |
| 14 June 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 14 June 2023 | Topic selection |
| 14 June 2023 | Topic selection. Routing update |
| 19 January 2023 (14:00) | Scoping workshop |
| 09 November 2022 - 07 December 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 20 May 2022 | In progress. Scoping commencing |
For further information on our processes and methods, please see our CHTE processes and methods manual